Commentary| Volume 19, ISSUE 1, P56-61, January 1997

Neoadjuvant progesterone therapy for primary breast cancer: rationale for a clinical trial

  • Ismail Jatoi
    Address correspondence to: Ismail Jatoi, MD, PhD, Department of Surgery, Attn: MCHE-SDG, Brooke Army Medical Center, 3851 Roger Brooke Drive, San Antonio, TX 78234-6200.
    Uniformed Services University of the Health Sciences, Bethesda, Maryland U.S.A.
    Department of Surgery, Brooke Army Medical Center, Fort Sam Houston, Texas U.S.A.
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.


      The hormonal milieu at the time of surgery may influence mortality and disease-free survival in patients with primary breast cancer. Indeed, there is evidence that circulating unopposed estrogen is detrimental and that the presence of circulating progesterone results in an improved disease-free and overall survival rate. Thus patients who receive neoadjuvant progesterone therapy may have a better outcome. A randomized controlled trial in which women with primary breast cancer receive either progesterone or placebo before surgery is urgently needed to confirm this hypothesis.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Badwe RA
        • Gregory WM
        • Chaudry MA
        • et al.
        Timing of surgery during the menstrual cycle and survival of premenopausal women with operable breast cancer.
        Lancet. 1991; 337: 1261-1264
        • Senie RT
        • Rosen PP
        • Rhodes PR
        • Lesser ML
        Timing of breast cancer excision during the menstrual cycle influences duration of disease-free survival.
        Ann Intern Med. 1991; 115: 337-342
        • Veronesi U
        • Luini A
        • Mariani L
        • et al.
        Effect of menstrual phase on surgical treatment of breast cancer.
        Lancet. 1994; 343: 1545-1547
        • Vyas JJ
        • Desai PB
        • Sampat MB
        • et al.
        Observation on Indian node-negative breast cancer patients: A multivariate analysis.
        J Surg Oncol. 1989; 42: 256-263
        • Mueller CB
        • Ames F
        • Anderson GD
        Breast cancer in 3558 women: Age as a significant prognostic determinant in the rate of dying and causes of death.
        Surgery. 1978; 83: 123-132
        • Boyd NF
        • Campbell JE
        • Germanson T
        • et al.
        Body weight and prognosis in breast cancer.
        J Natl Cancer Inst. 1981; 67: 785-789
        • Tretli S
        Height and weight in relation to breast cancer morbidity and mortality. A prospective study of 570,000 women in Norway.
        Int J Cancer. 1989; 44: 23-30
        • Sharp D
        Prospective look at breast surgery timing.
        Lancet. 1994; 344 (Commentary): 1013
        • Hrushesky WJM
        Menstrual timing of breast cancer resection: Prospective trial is overdue.
        J Natl Cancer Inst. 1995; 87: 143-144
        • Hrushesky WJM
        • Bluming AZ
        • Gruber SA
        • Sothern RB
        Menstrual influence on surgical cure of breast cancer.
        Lancet. 1989; 2: 949-952
        • Powles TJ
        • Ashley SE
        • Nash AE
        • et al.
        Menstrual surgical timing.
        Lancet. 1991; 337 (Letter): 1604
        • McGuire WL
        • Hilsenbeck S
        • Clark GM
        Optimal mastectomy timing.
        J Natl Cancer Inst. 1992; 84: 346-348
        • Fentiman IS
        • Gregory WM
        • Richards MA
        Effect of menstrual phase on surgical treatment of breast cancer.
        Lancet. 1994; 344: 402-403
        • Badwe RA
        Timing of surgery during the menstrual cycle for operable breast cancer.
        Cancer Top. 1993; 9: 42-43
        • Badwe RA
        • Wang DY
        • Gregory WM
        • et al.
        Serum progesterone at time of surgery and survival in women with premenopausal operable breast cancer.
        Eur J Cancer. 1994; 30A: 445-448
        • Grodin JM
        • Siiteri PK
        • MacDonald PC
        Source of estrogen production in post-menopausal women.
        J Clin Endocrinol Metab. 1973; 36: 207-214
        • Fentiman IS
        • Gregory WM
        The hormonal milieu and prognosis in operable breast cancer.
        Cancer Surv. 1993; 18: 149-163
        • Jatoi I
        • Mansi JL
        • Bliss JM
        • et al.
        Influence of menopause on bone marrow micrometastases in early breast cancer. Abstract. book 1.
        Sixteenth International Cancer Congress, New Delhi, India. 1994; : 160
        • Gunduz N
        • Fisher B
        • Saffer EA
        Effect of surgical removal on the growth and kinetics of residual tumor.
        Cancer Res. 1979; 39: 3861-3865
        • Fisher B
        • Gunduz N
        • Coyle J
        • et al.
        Presence of a growth-stimulating factor in serum following primary tumor removal in mice.
        Cancer Res. 1989; 49: 1996-2001
        • Wood WC
        Progress from clinical trials on breast cancer.
        Cancer. 1994; 74: 2606-2609